Charles T Spencer1, Jelena S Bezbradica2, Mireya G Ramos1, Chenoa D Arico1, Stephanie B Conant3, Pavlo Gilchuk3,4, Jennifer J Gray3, Mu Zheng3,5, Xinnan Niu3,5, William Hildebrand6, Andrew J Link3,5, Sebastian Joyce3,4. 1. Department of Biological Sciences, University of Texas at El Paso, El Paso, TX, USA. 2. Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. 3. Department of Pathology, Microbiology and Immunology, Nashville, TN, USA. 4. Veterans Administration Tennessee Valley Healthcare System, Nashville, TN, USA. 5. Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA. 6. Department of Microbiology and Immunology, University of Oklahoma Health Science Centre, Oklahoma City, OK, USA.
Abstract
PURPOSE: MHC class I presentation of peptides allows T cells to survey the cytoplasmic protein milieu of host cells. During infection, presentation of self peptides is, in part, replaced by presentation of microbial peptides. However, little is known about the self peptides presented during infection, despite the fact that microbial infections alter host cell gene expression patterns and protein metabolism. EXPERIMENTAL DESIGN: The self peptide repertoire presented by HLA-A*01;01, HLA-A*02;01, HLA-B*07;02, HLA-B*35;01, and HLA-B*45;01 (where HLA is human leukocyte antigen) was determined by tandem MS before and after vaccinia virus infection. RESULTS: We observed a profound alteration in the self peptide repertoire with hundreds of self peptides uniquely presented after infection for which we have coined the term "self peptidome shift." The fraction of novel self peptides presented following infection varied for different HLA class I molecules. A large part (approximately 40%) of the self peptidome shift arose from peptides derived from type I interferon-inducible genes, consistent with cellular responses to viral infection. Interestingly, approximately 12% of self peptides presented after infection showed allelic variation when searched against approximately 300 human genomes. CONCLUSION AND CLINICAL RELEVANCE: Self peptidome shift in a clinical transplant setting could result in alloreactivity by presenting new self peptides in the context of infection-induced inflammation.
PURPOSE:MHC class I presentation of peptides allows T cells to survey the cytoplasmic protein milieu of host cells. During infection, presentation of self peptides is, in part, replaced by presentation of microbial peptides. However, little is known about the self peptides presented during infection, despite the fact that microbial infections alter host cell gene expression patterns and protein metabolism. EXPERIMENTAL DESIGN: The self peptide repertoire presented by HLA-A*01;01, HLA-A*02;01, HLA-B*07;02, HLA-B*35;01, and HLA-B*45;01 (where HLA is human leukocyte antigen) was determined by tandem MS before and after vaccinia virus infection. RESULTS: We observed a profound alteration in the self peptide repertoire with hundreds of self peptides uniquely presented after infection for which we have coined the term "self peptidome shift." The fraction of novel self peptides presented following infection varied for different HLA class I molecules. A large part (approximately 40%) of the self peptidome shift arose from peptides derived from type I interferon-inducible genes, consistent with cellular responses to viral infection. Interestingly, approximately 12% of self peptides presented after infection showed allelic variation when searched against approximately 300 human genomes. CONCLUSION AND CLINICAL RELEVANCE: Self peptidome shift in a clinical transplant setting could result in alloreactivity by presenting new self peptides in the context of infection-induced inflammation.
Authors: E S Kuzina; E L Chernolovskaya; A A Kudriaeva; M A Zenkova; V D Knorre; E A Surina; N A Ponomarenko; T V Bobik; I V Smirnov; A V Bacheva; A A Belogurov; A G Gabibov; V V Vlasov Journal: Dokl Biochem Biophys Date: 2014-01-03 Impact factor: 0.788
Authors: Whitney A Macdonald; Zhenjun Chen; Stephanie Gras; Julia K Archbold; Fleur E Tynan; Craig S Clements; Mandvi Bharadwaj; Lars Kjer-Nielsen; Philippa M Saunders; Matthew C J Wilce; Fran Crawford; Brian Stadinsky; David Jackson; Andrew G Brooks; Anthony W Purcell; John W Kappler; Scott R Burrows; Jamie Rossjohn; James McCluskey Journal: Immunity Date: 2009-12-18 Impact factor: 31.745
Authors: Wieke Freudenburg; Madhav Gautam; Pradipta Chakraborty; Jared James; Jennifer Richards; Alison S Salvatori; Aaron Baldwin; Jill Schriewer; R Mark L Buller; John A Corbett; Dorota Skowyra Journal: J Clin Cell Immunol Date: 2013-04-23
Authors: Alexander Karlas; Nikolaus Machuy; Yujin Shin; Klaus-Peter Pleissner; Anita Artarini; Dagmar Heuer; Daniel Becker; Hany Khalil; Lesley A Ogilvie; Simone Hess; André P Mäurer; Elke Müller; Thorsten Wolff; Thomas Rudel; Thomas F Meyer Journal: Nature Date: 2010-01-17 Impact factor: 49.962
Authors: P S Ohashi; S Oehen; K Buerki; H Pircher; C T Ohashi; B Odermatt; B Malissen; R M Zinkernagel; H Hengartner Journal: Cell Date: 1991-04-19 Impact factor: 41.582
Authors: Shelley R Starck; Yongkai Ow; Vivian Jiang; Maria Tokuyama; Mark Rivera; Xin Qi; Richard W Roberts; Nilabh Shastri Journal: PLoS One Date: 2008-10-21 Impact factor: 3.240
Authors: Maria P Bettinotti; Deborah Ferriola; Jamie L Duke; Timothy L Mosbruger; Nikolaos Tairis; Lawrence Jennings; Lisa V Kalman; Dimitri Monos Journal: J Mol Diagn Date: 2018-06-26 Impact factor: 5.568
Authors: J Patrick Murphy; Youra Kim; Derek R Clements; Prathyusha Konda; Heiko Schuster; Daniel J Kowalewski; Joao A Paulo; Alejandro M Cohen; Stefan Stevanovic; Steven P Gygi; Shashi Gujar Journal: J Proteome Res Date: 2019-05-29 Impact factor: 4.466
Authors: Daniel T Dugger; Monica Fung; Lorna Zlock; Saharai Caldera; Louis Sharp; Steven R Hays; Jonathan P Singer; Lorriana E Leard; Jefferey A Golden; Rupal J Shah; Jasleen Kukreja; Erin Gordon; Walter Finkbeiner; Mary Ellen Kleinhenz; Chaz Langelier; John R Greenland Journal: Cell Rep Med Date: 2020-07-21